These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22444196)

  • 1. Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
    Nezami N; Safa J; Salari B; Ghorashi S; Khosraviani K; Davari-Farid S; Hashemi-Aghdam Y; Nargabad ON; Tabrizi JS
    Nucleosides Nucleotides Nucleic Acids; 2012 Apr; 31(4):353-63. PubMed ID: 22444196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.
    Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Nezami N; Safa J; Montazer-Saheb S
    Iran J Kidney Dis; 2009 Apr; 3(2):93-8. PubMed ID: 19395785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
    Nezami N; Safa J; Eftekhar-Sadat AT; Salari B; Ghorashi S; Sakhaee K; Khosraviani K
    Clin Biochem; 2010 Nov; 43(16-17):1294-9. PubMed ID: 20727867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
    Gholamin S; Razavi SM; Taghavi-Garmestani SM; Ghorbanihaghjo A; Rashtchizadeh N; Safa J; Vatankhah AM; Azizi T; Argani H
    Iran J Kidney Dis; 2014 May; 8(3):201-6. PubMed ID: 24878942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
    Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
    Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy.
    Nezami N; Ghorbanihaghjo A; Argani H; Safa J; Rashtchizadeh N; Vatankhah AM; Salari B; Hajhosseini B
    Clin Biochem; 2011 Feb; 44(2-3):165-70. PubMed ID: 20970413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lovastatin on serum lipids in patients with nonfamilial primary hypercholesterolemia.
    Itskovitz HD; Flamenbaum W; De Gaetano C; Pritchard KA; Stemerman MB
    Clin Ther; 1989; 11(6):862-72. PubMed ID: 2611825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood lipid, glucose and uric acid in people with subclinical hypothyroidism].
    Liang LB; Zhang M; Huang HJ; Wang YJ; Li SQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):954-6. PubMed ID: 24490510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
    Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
    Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serum uric acid with different levels of glucose and related factors.
    Yuan HJ; Yang XG; Shi XY; Tian R; Zhao ZG
    Chin Med J (Engl); 2011 May; 124(10):1443-8. PubMed ID: 21740795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between adiponectin and leptin, and blood lipids in hyperlipidemia patients treated with red yeast rice.
    Lee CY; Jan MS; Yu MC; Lin CC; Wei JC; Shih HC
    Forsch Komplementmed; 2013; 20(3):197-203. PubMed ID: 23860021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum uric acid in type 2 diabetic patients complicated by stroke].
    Guan MP; Xue YM; Shen J; Zhou L; Gao F; Liu SQ; Li CZ
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Jan; 22(1):70-1. PubMed ID: 12390852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study.
    Sadighi A; Safa J; Vatankhah AM; Ghorashi S; Aharilahagh A; Davari-Farid S; Nezami-Nargabad O; Naghavi-Behzad M; Piri R; Pishahang P; Babapoor-Farrokhran S; Fakour S; Ghodratnezhad-Azar N
    Niger Med J; 2016; 57(5):253-259. PubMed ID: 27833243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V.
    Biesenbach G; Zazgornik J
    Clin Nephrol; 1992 Jun; 37(6):274-9. PubMed ID: 1638777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.